PPARA and Insulin resistance: Thus, compounds that stimulate both PPARα and PPARγ (dual PPARα/γ agonists) should additively improve both lipid and glucose abnormalities in animal models and human subjects with insulin resistance (IR) and/or type 2 diabetes (T2DM).